Hopkinson Craig C.

Hopkinson Craig C., Chief Medical Officer and EVP of R&D at Alkermes plc (ALKS), has been a consistent seller of company stock over the past year, with no open-market purchases recorded in his recent Form 4 filings. Across 39 total transactions, his sell-side activity totals roughly $3.52 million, all in ALKS shares. The pattern is dominated by recurring monthly sales tied to option exercises—typically around $96,700 in exercised options paired with sales ranging from $267,000 to $437,000. These transactions, occurring on the first of each month from March through August 2026, suggest a systematic liquidation of vested equity rather than a one-off repositioning. The most recent filings, dated August 3, 2026, show a sale of $437,220 alongside two option exercises worth a combined $122,404. This follows similar monthly activity in July ($463,621 in sales), June ($375,044), May ($300,560), and April ($319,604). Notably, there are zero buy-side transactions (code "P") in the entire dataset, and the only non-sale events are compensation-related: two zero-value grants (code "A") in March 2026 and several tax-withholding dispositions (code "F") in February 2026, which are automatic and not discretionary. The absence of any open-market purchases, combined with the steady cadence of sales, points to a clear net-selling bias by the executive over the observed period. While the dollar amounts are substantial, the structure of the trades—monthly option exercises immediately followed by sales—is typical of a pre-arranged 10b5-1 plan or routine equity monetization. The February "F" transactions, totaling roughly $675,000 in withheld shares, further indicate that a significant portion of his compensation is being converted to cash to cover tax obligations. Overall, Hopkinson’s activity reflects a consistent reduction of his ALKS position, with no signals of accumulation or bullish conviction from his own wallet.